Search

Displaying results 3551 - 3560 of 10000 in total
  1. Drug

    Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11041
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Mixtures: AGRIPPAL 2.5 ML IM/SC ENJ.ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR
  2. Drug

    Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15520
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Mixtures: INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 ML
  3. Drug

    AT1391

    go.drugbank.com/drugs/DB05120
    Experimental

    AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.

  4. Drug

    Tralesinidase alfa

    go.drugbank.com/drugs/DB17657
    Investigational

    It is being investigated for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome B.[A258828] … Tralesinidase alfa is a chimeric fusion protein comprised of recombinant human NAGLU and a modified human insulin-like growth factor 2.

    Synonyms: Recombinant human NAGLU-insulin-like growth factor II
  5. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. … It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy.

    Categories: Estrogen Receptor Modulators, Selective Estrogen Receptor Modulators
  6. Drug

    Edetic acid

    go.drugbank.com/drugs/DB00974
    ApprovedInvestigationalVet approved

    It is used in pharmaceutical manufacturing and as a food additive.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Diiodohydroxyquinoline

    go.drugbank.com/drugs/DB09115
    Approved

    Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. … Iodoquinol is not currently available in any FDA-approved products.

  8. Drug

    Halofuginone

    go.drugbank.com/drugs/DB04866
    InvestigationalVet approved

    Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000. … Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression.

  9. Drug

    Chloramphenicol succinate

    go.drugbank.com/drugs/DB07565
    Approved

    Chloramphenicol succinate is an ester prodrug of [chloramphenicol].[A192987] Chloramphenicol is a bacteriostatic antibiotic.

  10. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). … [L45469] In February 2023, Kinnate Biopharma received Fast Track designation from the FDA for KIN-3248 to treat unresectable, locally advanced or metastatic cholangiocarcinoma (CCA).[L45474]